Refractory Epilepsy
Conditions
Keywords
Seizures, Epilepsy
Brief summary
This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)
Detailed description
To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* Diagnosis of refractory epilepsy * Body weight 26 to 111 kilogram (kg) inclusive * Other inclusion criteria apply
Exclusion criteria
* Male or female subject who is not surgically sterile or female subject who is less than 2 years postmenopausal, and does not agree to use a highly effective birth control method during the study and up to 3 months after the last dose of investigational product * Female subject who is pregnant, breastfeeding, or planning to become pregnant * Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam * Other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC 0-24h | 24 hours | Relative bioavailability based on area under time plasma concentration curve. |
| Cmax | 24 hours | Relative bioavailability based on maximum observed plasma concentration. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Focused Nasal Exam (Part A) | pre-dose (day 1) up to 24 hours post-dose | A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded none to Grade 4 septal perforation. Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted) |
| Focused Nasal Exam (Part B) | pre-dose (day 1) up to 24 hours post-dose | A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted) |
| Smell Identification Test (SIT) | day 1 up to day 31 | The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different scratch and sniff strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender. |
| Taste Change Questionnaire | Up to 24 hours | Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented. |
Countries
United States
Participant flow
Recruitment details
This is a randomized crossover study with 78 subjects total.
Participants by arm
| Arm | Count |
|---|---|
| All Participants DZNS (Diazepam Nasal Spray) vs DRG (Diazepam rectal gel) | 78 |
| Total | 78 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Categorical <=18 years | 2 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 75 Participants |
| Age, Continuous | 41.4 years STANDARD_DEVIATION 13.52 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 73 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 13 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 6 Participants |
| Race (NIH/OMB) White | 57 Participants |
| Region of Enrollment United States | 78 Participants |
| Sex: Female, Male Female | 51 Participants |
| Sex: Female, Male Male | 27 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 78 | 0 / 78 |
| other Total, other adverse events | 60 / 78 | 20 / 78 |
| serious Total, serious adverse events | 0 / 78 | 0 / 78 |
Outcome results
AUC 0-24h
Relative bioavailability based on area under time plasma concentration curve.
Time frame: 24 hours
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Single Dose of Diazapam Nasal Spray (DZNS) | AUC 0-24h | 1357.7 ng*h/mL | Standard Deviation 802.78 |
| Single Dose of Diazapam Rectal Gel (DRG) | AUC 0-24h | 2117.9 ng*h/mL | Standard Deviation 996.27 |
Cmax
Relative bioavailability based on maximum observed plasma concentration.
Time frame: 24 hours
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Single Dose of Diazapam Nasal Spray (DZNS) | Cmax | 157.0 ng/mL | Standard Deviation 120.15 |
| Single Dose of Diazapam Rectal Gel (DRG) | Cmax | 309.3 ng/mL | Standard Deviation 137.95 |
Focused Nasal Exam (Part A)
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded none to Grade 4 septal perforation. Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Time frame: pre-dose (day 1) up to 24 hours post-dose
Population: Safety population Cohort 1. (Accessed only for DZNS Arm)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 64 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part A) | Grade 1a | 1 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part A) | Grade 1b | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part A) | Grade 3 | 0 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part A) | Grade 3 | 0 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part A) | Grade 1b | 0 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 6 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part A) | Grade 1a | 3 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part A) | Grade 1b | 2 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part A) | Grade 1a | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part A) | Grade 3 | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part A) | Grade 1a | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part A) | Grade 1b | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part A) | Grade 3 | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part A) | Grade 3 | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part A) | Grade 1a | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part A) | Grade 1b | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Focused Nasal Exam (Part A) | Grade 1a | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Focused Nasal Exam (Part A) | Grade 1b | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Focused Nasal Exam (Part A) | Grade 3 | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Focused Nasal Exam (Part A) | Grade 1b | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Focused Nasal Exam (Part A) | Nasal Irritation at Baseline - NONE | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Focused Nasal Exam (Part A) | Grade 1a | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Focused Nasal Exam (Part A) | Grade 3 | 0 Participants |
Focused Nasal Exam (Part B)
A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)
Time frame: pre-dose (day 1) up to 24 hours post-dose
Population: The Safety population / Cohort 1. (Accessed only for DZNS Arm)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | At Baseline: Mucosal Erythema - None | 67 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | At Baseline: Mucosal Edema-None | 70 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | Mucosal Bleeding/Epistaxis - Mild | 1 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | At Baseline: Mucosal Bleeding/Epistaxis - None | 76 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | At Baseline: Nasal Discharge - None | 67 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | Nasal Discharge - Moderate | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | At Baseline: Crusting of Mucosa - None | 77 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | Mucosal Edema - Moderate | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | Mucosal Edrythema - Mild | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | Nasal Discharge - Mild | 1 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Focused Nasal Exam (Part B) | Mucosal Edema - Mild | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | Nasal Discharge - Mild | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | At Baseline: Mucosal Erythema - None | 6 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | Nasal Discharge - Moderate | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | Mucosal Edema - Mild | 3 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | At Baseline: Mucosal Edema-None | 3 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | Mucosal Bleeding/Epistaxis - Mild | 0 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | At Baseline: Mucosal Bleeding/Epistaxis - None | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | Mucosal Edema - Moderate | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | At Baseline: Crusting of Mucosa - None | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | At Baseline: Nasal Discharge - None | 7 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Focused Nasal Exam (Part B) | Mucosal Edrythema - Mild | 5 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | Nasal Discharge - Moderate | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | At Baseline: Mucosal Edema-None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | Mucosal Edema - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | Mucosal Edema - Moderate | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | At Baseline: Nasal Discharge - None | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | Nasal Discharge - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | At Baseline: Mucosal Erythema - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | Mucosal Edrythema - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | At Baseline: Mucosal Bleeding/Epistaxis - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | Mucosal Bleeding/Epistaxis - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Focused Nasal Exam (Part B) | At Baseline: Crusting of Mucosa - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | At Baseline: Mucosal Erythema - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | At Baseline: Nasal Discharge - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | At Baseline: Mucosal Edema-None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | Mucosal Edrythema - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | Mucosal Edema - Moderate | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | At Baseline: Mucosal Bleeding/Epistaxis - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | Mucosal Edema - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | At Baseline: Crusting of Mucosa - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | Mucosal Bleeding/Epistaxis - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | Nasal Discharge - Moderate | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Focused Nasal Exam (Part B) | Nasal Discharge - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | Mucosal Bleeding/Epistaxis - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | At Baseline: Mucosal Erythema - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | At Baseline: Nasal Discharge - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | At Baseline: Mucosal Bleeding/Epistaxis - None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | At Baseline: Mucosal Edema-None | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | Nasal Discharge - Moderate | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | Mucosal Edrythema - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | Mucosal Edema - Moderate | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | Nasal Discharge - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | Mucosal Edema - Mild | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Focused Nasal Exam (Part B) | At Baseline: Crusting of Mucosa - None | 0 Participants |
Smell Identification Test (SIT)
The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different scratch and sniff strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.
Time frame: day 1 up to day 31
Population: Safety Population / Cohort 1. (Accessed only for DZNS Arm)
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | Mild Microsmia | 2 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | Missing | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | Anosmia | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | At BASELINE: Normosmia | 19 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | Severe Microsmia | 0 Participants |
| Single Dose of Diazapam Nasal Spray (DZNS) | Smell Identification Test (SIT) | Moderate Microsmia | 2 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | At BASELINE: Normosmia | 10 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | Anosmia | 0 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | Mild Microsmia | 10 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | Moderate Microsmia | 3 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | Severe Microsmia | 1 Participants |
| Single Dose of Diazapam Rectal Gel (DRG) | Smell Identification Test (SIT) | Missing | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | Moderate Microsmia | 3 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | Mild Microsmia | 5 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | Severe Microsmia | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | Anosmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | Missing | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | At BASELINE: Normosmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 1b | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | Missing | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | Mild Microsmia | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | Moderate Microsmia | 6 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | Severe Microsmia | 4 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | At BASELINE: Normosmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 2 | Smell Identification Test (SIT) | Anosmia | 2 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | At BASELINE: Normosmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | Anosmia | 3 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | Missing | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | Mild Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | Moderate Microsmia | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | Severe Microsmia | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 3 | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | Missing | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | Severe Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | Anosmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | Mild Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | Moderate Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Grade 4 | Smell Identification Test (SIT) | At BASELINE: Normosmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | At BASELINE: Normosmia | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | Missing | 2 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | Mild Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | Severe Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | Anosmia | 1 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | Moderate Microsmia | 0 Participants |
| DZNS - At 24 Hours Post-Dose - Missing | Smell Identification Test (SIT) | Probable Malingering | 0 Participants |
Taste Change Questionnaire
Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.
Time frame: Up to 24 hours
Population: Safety Population / Cohort 1. (Accessed only for DZNS Arm)
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 5 mins Post-Dose | 6.5 units on a scale | Standard Deviation 3.57 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 15 mins Post-Dose | 4.6 units on a scale | Standard Deviation 3.09 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 30 mins Post Dose | 2.8 units on a scale | Standard Deviation 2.75 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 1 hr Post Dose | 1.0 units on a scale | Standard Deviation 1.45 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 2 hrs Post-Dose | 0.3 units on a scale | Standard Deviation 0.48 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 4 hrs Post-Dose | 0.1 units on a scale | Standard Deviation 0.36 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 8 hrs Post-Dose | 0.0 units on a scale | Standard Deviation 0 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 12 hrs Post-Dose | 0.0 units on a scale | Standard Deviation 0 |
| Single Dose of Diazapam Nasal Spray (DZNS) | Taste Change Questionnaire | 24 hrs Post-Dose | 0.0 units on a scale | Standard Deviation 0 |